Aegerion Pulls IPO

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic disease, has withdrawn registration of an IPO designed to raise upwards of $70 million. It blamed “market conditions” for the decision. Lehman Brothers had been serving as lead underwriter. Aegerion raised around $22.5 million in Series A funding in 2005 from firms like Alta Partners, Advent International, Index Ventures, MVM Life Science Partners and Scheer & Co.